ArticleJournal of neurology2026
Outcome associations of CSF total tau in suspected non-Alzheimer pathophysiology.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysiology" (SNAP), according to the 2018 research framework for a biological definition of Alzheimer's disease (AD). The SNAP concept remains incompletely characterized, and associations of amyloid and tau biomarkers with survival outcomes in the SNAP context remain unclear.
methodsWe conducted a retrospective study in patients with a SNAP biomarker constellation, recruited from two tertiary centers between 2019 and 2024. We extracted clinical demographic variables, biomarker results, and survival times to all-cause-mortality or last seen from electronic health records. SNAP patients were defined based on normal cerebrospinal fluid (CSF) levels of amyloid-β
resultsCompared across amyloid-tau-neurodegeneration-defined categories, patients with SNAP had a shorter median survival than those with AD (31 vs. 42 months), while the Alzheimer's pathological change with concurrent neurodegeneration (APC + N) category exhibited the shortest median survival at 16 months. Patients with SNAP (n = 99) had a median age of 72 (inter-quartile range, IQR: 64; 77) years and a median follow-up time of 12 (IQR 1;27, max. 60) months. Among selected variables, tTau performed best in predicting survival during the follow-up period (area under the curve, AUC = 0.83) in non-prion SNAP, followed by the pTau/tTau ratio (AUC = 0.82). The optimal prognostic tTau cutpoint of ≥ 600 pg/mL was higher than the age-adjusted diagnostic reference (300-500 pg/mL). Patients with SNAP exhibiting higher tTau levels or a reduced pTau-181/tTau ratio had significantly shorter median survival times. Multivariable Cox hazard modeling confirmed tTau to be independently associated with survival with a hazard ratio of 6.1-6.8 (p < 0.001).
conclusionWe have identified CSF tTau as a novel predictor of survival in patients with SNAP. Although this descriptive diagnosis encompasses primarily various idiopathic neurodegenerative causes, we also demonstrate tTau's prognostic value in the context of secondary neurodegenerative processes. This finding can enhance prognostication in clinical settings.
Indexed as
Identifiers
42060129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.